Satellos Bioscience Inc
TSX:MSCL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Satellos Bioscience Inc
TSX:MSCL
|
CA |
|
T
|
Tycoons Worldwide Group Thailand PCL
SET:TYCN
|
TH |
Intrinsic Value
The intrinsic value of Satellos Bioscience Inc (MSCL) under the Base Case is 2.33 CAD per share.
Compared with the current market price of 9.71 CAD, the stock appears
Overvalued by 76% .
The intrinsic value is calculated using the DCF method.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What Satellos Bioscience Does
Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2006-12-01. The firm is focused on restoring natural muscle repair and regeneration in degenerative muscle diseases. Through its research, the Company has developed SAT-3247, a first-of-its-kind, orally administered small molecule drug designed to address deficits in muscle repair and regeneration.
- Headquarters
- Canada CA
- Employees
- 20
- IPO date
- Dec 1, 2006
Earnings Waterfall
Satellos Bioscience Inc
The intrinsic value for Satellos Bioscience Inc (MSCL) under the Base Case is 2.33 CAD.
Compared with the current market price of 9.71 CAD, the stock appears Overvalued by 76% .